Iodine-Driven Three-Component Reaction of Isocyanides, Amines, and TsNXNa (X = Br, Cl): A Facile, Metal-Free Approach towards N-Sulfonyl Guanidines

Abstract

This work illustrates an expeditious, highly efficient, metal-, base-, and oxidant-free approach towards synthesizing N-sulfonyl guanidines via a three-component reaction system comprising isocyanides, amines, and TsNXNa (X = Br, Cl). The reaction proceeds via the formation of an isolable carbodiimide intermediate. The synthetic protocol emerges as a promising route for a simple, efficient, and rapid transformation into a diverse range of N-sulfonyl guanidines under mild reaction conditions.

Key words

isocyanide - bromamine-T - carbodiimide - metal-free - guanidine

Publikationsverlauf

Eingereicht: 26. Februar 2025

Angenommen nach Revision: 07. April 2025

Accepted Manuscript online:
07. April 2025

Artikel online veröffentlicht:
20. Mai 2025

• References and Notes

• 1 Strecker A. Justus Liebigs Ann. Chem. 1861; 118: 151
• 2 Saczewski F, Balewski Ł. Expert Opin. Ther. Pat. 2009; 19: 1417
• 3 Berlinck RG. S. Nat. Prod. Rep. 1996; 13: 377
• 4 Berlinck RG. S, Burtoloso AC. B, Kossuga MH. Nat. Prod. Rep. 2008; 25: 919
• 5 Berlinck RG. S, Burtoloso AC. B, Trindade-Silva AE, Romminger S, Morais RP, Bandeira K, Mizuno CM. Nat. Prod. Rep. 2010; 27: 1871
• 6 Berlinck RG. S, Trindade-Silva AE, Santos MF. C. Nat. Prod. Rep. 2012; 29: 1382
• 7 Schmuck C. Coord. Chem. Rev. 2006; 250: 3053
• 8 Castagnolo D, Schenone S, Botta M. Chem. Rev. 2011; 111: 5247
• 9 Leow D, Tan C. Chem. Asian J. 2009; 4: 488
• 10 Leow D, Tan C.-H. Synlett 2010; 1589
• 11 Terada MJ. Synth. Org. Chem. Jpn. 2010; 68: 1159
• 12 Fu X, Tan C.-H. Chem. Commun. 2011; 47: 8210
• 13 Sohtome Y, Nagasawa K. Chem. Commun. 2012; 48: 7777
• 14 Ishikawa T, Kumamoto T. Synthesis 2006; 737
• 15 Superbases for Organic Synthesis: Guanidines, Amidines, Phosphazenes and Related Organocatalysts, 1^st edition. Ishikawa T. Wiley; New York: 2009
• 16 Ishikawa T. Chem. Pharm. Bull. 2010; 58: 1555
• 17 Alder RW, Bowman PS, Steele WR. S, Winterman DR. Chem. Commun. (London) 1968; 723
• 18 Oediger H, Möller F, Eiter K. Synthesis 1972; 591
• 19 Taylor JE, Bull SD, Williams JM. J. Chem. Soc. Rev. 2012; 41: 2109
• 20 Berlinck RG. S. Nat. Prod. Rep. 1999; 16: 339
• 21 Culhane NS, Lettieri SL, Skae JR. Pharmacotherapy 2005; 25: 990
• 22 Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Drugs 1983; 26: 212
• 23 Goswami D, Gurule S, Lahiry A, Anand A, Khuroo A, Monif T. Future Sci. OA 2016; 2: 92
• 24 Brogden RN, Heel RC, Speight TM, Avery GS. Drugs 1978; 15: 93
• 25 Yendapally R, Sikazwe D, Kim SS, Ramsinghani S, Fraser-Spears R, Witte AP, La-Viola B. Drug Dev. Res. 2020; 81: 390
• 26 Greenhill JV, Lue P. Prog. Med. Chem. 1993; 30: 203
• 27 Kim S.-H, Semenya D, Castagnolo D. Eur. J. Med. Chem. 2021; 216: 113293
• 28 Wang W, Li J, Xu L, Dong J. Org. Lett. 2024; 26: 3202
• 29 Manimala JC, Anslyn EV. Eur. J. Org. Chem. 2002; 3909
• 30 Alonso-Moreno C, Antiñolo A, Carrillo-Hermosilla F, Otero A. Chem. Soc. Rev. 2014; 43: 3406
• 31 Zhang W.-X, Xu L, Xi Z. Chem. Commun. 2015; 51: 254
• 32 Zhu T, Wang S, Wei T, Ji S. Adv. Synth. Catal. 2015; 357: 823
• 33 Zhang Z, Li Z, Fu B, Zhang Z. Chem. Commun. 2015; 51: 16312
• 34 Zhang Z, Huang B, Qiao G, Zhu L, Xiao F, Chen F, Fu B, Zhang Z. Angew. Chem. Int. Ed. 2017; 56: 4320
• 35 Gu Z.-Y, Liu Y, Wang F, Bao X, Wang S.-Y, Ji S.-J. ACS Catal. 2017; 7: 3893
• 36 Qiao G, Zhang Z, Huang B, Zhu L, Xiao F, Zhang Z. Synthesis 2018; 50: 330
• 37 Fang Y, Yang J.-M, Zhang R, Wang S.-Y, Ji S.-J. Org. Chem. Front. 2019; 6: 3383
• 38 Li J, Neuville L. Org. Lett. 2013; 15: 6124
• 39 Tsubokura K, Iwata T, Taichi M, Kurbangalieva A, Fukase K, Nakao Y, Tanaka K. Synlett 2014; 25: 1302
• 40 Li J, Wang H, Hou Y, Yu W, Xu S, Zhang Y. Eur. J. Org. Chem. 2016; 2388
• 41 Hazarika D, Borah AJ, Phukan P. Chem. Commun. 2019; 55: 1418
• 42 Goswami D, Mishra D, Phukan P. Mol. Diversity 2023; 27: 2545
• 43 Phukan P, Bhattacharjee M, Phukan P. Asian J. Org. Chem. 2025; 14: e202500176
• 44 Mishra D, Rajkhowa S, Phukan P. iScience 2023; 26: 107258
• 45 Vyas R, Chanda BM, Bedekar AV. Tetrahedron Lett. 1998; 39: 4715
• 46 Chanda BM, Vyas R, Bedekar AV. J. Org. Chem. 2001; 66: 30
• 47 Mishra D, Phukan P. J. Org. Chem. 2021; 86: 17581
• 48 Mishra D, Kashyap S, Phukan P. J. Org. Chem. 2023; 88: 9401
• 49 Bora P, Bez G. Chem. Commun. 2018; 54: 8363
• 50 Kashyap S, Phukan P. Synlett 2024; 35: 753
• 51 General Procedure for the Preparation of Bromamine-T ⁵⁰ To a vigorously stirred solution of NaOH (240 mg) in 1.5 mL of distilled water under ice-cold conditions, 1 g of TsNBr₂ was added in portions. The precipitate formed was filtered under suction and dried over anhydrous P₂O₅.
• 52 General Procedure for the Synthesis of N-Sulfonyl Guanidines and Characterization To a vigorously stirred solution of isocyanide (0.5 mmol, 1.0 equiv) in CHCl₃ (3 mL), iodine (15 mol%), TsNXNa (X = Br, Cl) (1.25 mmol, 2.5 equiv), and amine (0.5 mmol, 1 equiv) were added and allowed to stir continuously at room temperature for 1 h. After the completion of the reaction as monitored by TLC, the reaction mixture was extracted with ethyl acetate and washed with Na₂S₂O₃. The organic layer was dried over anhydrous Na₂SO₄, concentrated under reduced pressure, and purified by column chromatography on silica gel (230–400 mesh) using petroleum ether and ethyl acetate as eluent. N-[(tert-Butylamino)(dihexylamino)methylene]-4-methylbenzenesulfonamide (4d) White solid (81%, 177 mg); mp 50–52 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.74 (dd, J = 8.1, 1.4 Hz, 2 H), 7.17 (d, J = 7.2 Hz, 2 H), 5.36 (br s, 1 H), 3.31 (t, J = 7.6 Hz, 4 H), 2.33 (s, 3 H), 1.47 (s, 4 H), 1.25–1.17 (m, 21 H), 0.83 (t, J = 5.2 Hz, 6 H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 158.0, 142.0, 141.0, 128.7, 125.8, 54.2, 49.9, 31.2, 29.8, 27.4, 26.3, 22.3, 21.2, 13.8. IR (KBr): ν = 3331, 2938, 2863, 1563, 1500, 1454, 1263, 1140, 1079, 951, 715, 537 cm^–1. HRMS (ESI): m/z calcd for C₂₄H₄₄N₃O₂S [M + H]⁺: 438.3149; found: 438.3159. N-(tert-Butyl)-N′-tosylazepane-1-carboximidamide (4i) White solid (68%, 128 mg); mp 62–64 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (d, J = 8 Hz, 2 H), 7.19 (d, J = 8 Hz, 2 H), 4.91 (br s, 1 H), 3.59 (t, J = 6 Hz, 4 H), 2.35 (s, 3 H), 1.74 (s, 4 H), 1.56 (s, 4 H), 1.14 (s, 9 H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 157.0, 142.5, 140.8, 128.7, 125.7, 53.4, 50.5, 29.6, 27.7, 27.5, 21.2. IR (KBr): ν = 3314, 2932, 2258, 1562, 1500, 1418, 1262, 1184, 1074, 863, 709, 543 cm^–1. HRMS (ESI): m/z calcd for C₁₈H₃₀N₃O₂S [M + H]⁺: 352.2053; found: 352.2056. Ethyl-1-[N-(tert-butyl)-N′-tosylcarbamimidoyl]piperidine-3-carboxylate (4j): White solid (65%, 133 mg); mp 98–100 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (d, J = 8 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 6.51 (br s, 1 H), 4.23–4.10 (m, 2 H), 3.86–3.73 (m, 2 H), 3.51–3.38 (m, 2 H), 2.68 (p, J = 4.4 Hz, 1 H), 2.35 (s, 3 H), 2.13–2.09 (m, 1 H), 1.90–1.81 (m, 1 H), 1.66–1.62 (m, 1 H), 1.48–1.36 (m, 1 H), 1.25 (t, J = 6.8 Hz, 3 H), 1.12 (s, 9 H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 174.5, 156.9, 142.2, 140.9, 128.7, 125.7, 61.2, 52.4, 49.8, 40.1, 29.3, 26.6, 23.5, 21.2, 14.0. IR (KBr): ν = 3324, 2973, 2326, 1727, 1562, 1521, 1438, 1260, 1170, 1144, 1110, 1079, 1029, 964, 891, 858, 772, 709, 660, 582, 532 cm^–1. HRMS (ESI): m/z calcd for C₂₀H₃₂N₃O₄S [M + H]⁺: 410.2108; found: 410.2110.